Success Metrics

Active Trials

5(63%)

Phase Distribution

Ph phase_3

25%

Ph phase_2

38%

Ph phase_1

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

3(37.5%)

Phase 2Efficacy & side effects

3(37.5%)

Phase 3Large-scale testing

2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(7)

Other(1)

Detailed Status

Recruiting5

Not yet recruiting1

Enrolling by invitation1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 13 (37.5%)

Phase 23 (37.5%)

Phase 32 (25.0%)

Trials by Status

not_yet_recruiting113%

enrolling_by_invitation113%

recruiting563%

unknown113%

Recent Activity

5 active trials

Showing 5 of 8

enrolling_by_invitationphase_3

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

NCT06281964

recruitingphase_2

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

NCT07336732

recruitingphase_1

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

NCT06343064

recruitingphase_2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

NCT06574347

not_yet_recruitingphase_3

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

NCT06970782

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT06281964Phase 3

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Enrolling By Invitation

NCT07336732Phase 2

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Recruiting

NCT06343064Phase 1

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Recruiting

NCT06574347Phase 2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Recruiting

NCT06970782Phase 3

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Not Yet Recruiting

NCT06046495Phase 1

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Recruiting

NCT06015503Phase 2

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

Recruiting

NCT05347628Phase 1

Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Unknown

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8